Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cheng-Kung University Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05892146CT.gov Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction | — | Unknown | — | — | — |
NCT03760588CT.gov Prevention of Cardiac Dysfunction During Breast Cancer Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Heart Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sacubitril (this asset) | National Cheng-Kung University Hospital | P2 | B · 57 |
| Empagliflozin | Jacob Moller | P4 | BB |
| Finerenone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | BB |
| Carvedilol | Abramson Cancer Center at Penn Medicine | P3 | BB |
| Semaglutide | University Medical Centre Ljubljana | P2/3 | BB |
| Rivaroxaban | Janssen Research & Development, LLC | P3 | B |
| Dapagliflozin | University Medical Centre Ljubljana | P3 | B |
| Sacubitril Valsartan | Silesian Centre for Heart Diseases | P4 | B |
| Spironolactone | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | P4 | B |
+32 more in the Heart Failure cohort
Other indications for Sacubitril
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypertensive Disorder | — | P4 | BB · 67 |
| Breast Cancer | — | P2 | B · 57 |
| Obesity Disorder | — | P2/3 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sacubitril in Heart Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sacubitril-heart-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →